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Smar To investigate possible relationships between genetic alterations and hormonal deregulation during
breast cancer development and/or progesson, we examined 616 primary breast cancers for loss of
heterozygosity (LbOH) at chromosomal regions 16q24, 17p13.3 and 17q21, and for amplfications ofthe ERBB2
and c-MYC loci. A comparison of oestrogen receptor (ER) and progesterone receptor (PgR) status in tumour
cells with data concerning these genetic alterations revealed that LOH at 17q21 was significantly correlated
with absence ofoestrogen receptors (ER) (P<0.0003) or progesterone receptors (PgR) (P<0.0001), and with
the absence of both (P<O.O001). Similarly, a sgnificnt assocation was observed between amplfiation of
ERPB2 and the absence of either ER or PgR1 LOH at 17p13.3 was associated with the absence of PgR
(P<O.O1). These data sugget a possible relationship between specific genetic changes on chromosome 17 and
hormonal deregulation in the progression of breast cancer.
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It is well known that breast carcinogenesis involves
cumulative genetic alterations in oncogenes and tumour-
suppressor genes (Callahan and Campbell, 1989; Sato et al.,
1990, 1991). Amplification of oncogenes such as ERBR2 and
c-MYC, and losses of heterozygosity (LOH) at 16q24,
17pL3.3 and 17q21, which refect inactivation of tumour-
suppressor genes in these chromosomal regions, have been
found in this type of cancer (Callahan and Campbell, 1989;
Sato et al., 1990, 1991; Cornelis et al., 1993). On the other
hand, it is known that oestrogen and other steroid hormones
play a signifiant role in the aetiology ofbreast cancer on the
basis of results from epidemiological, clinical and in vitro
studies (Wittlife, 1984; Henderson et al., 1988; Thompson et
al., 1990; Beck and Edwards, 1991; Martin, 1991). Oestrogen
is the primary hormonal stimulant for proliferation of breast
epithelial cells; proliferatng cells appear to sustain a higher
risk of undergoing genetic alterations and malignant trans-
formation.
Breast cancers in early stages generally maintain oestrogen-
dependent growth. During their progression, however, some
lose hormonal control. Their status in this respect, i.e. the
hormone dependency or independency of the breast tumour,
can be monitored by measurement of oestrogen/progesterone
receptors (Wittlife, 1984; Beck and Edwards, 1991; Martin,
1991; Horwitz, 1993). Understanding the relationships
between genetic alterations and deregulation of hormonal
control is of central importance to considerations of aetio-
logical factors in breast carcinogenesis. Tlherefore, we inves-
tigated 616 primary breast cancers for oestrogen/progesterone
receptor status and attempted to correlate these data with
five genetic alterations thought to be important in breast
carcinogenesis, i.e. amplification of c-MYC and ERBB2 and
LOH at chromosomal regions 16q24, 17pl3.3 and 17q21.
Material and methods
Twnow specimens
Of the patients with primary breast cancer who underwent
surgery at the Cancer Institute Hospital during the period
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September 1989 to December 1993, all 616 patients from
whom tumours and their corresponding non-cancerous tis-
sues were available were included in the present study; part
of this study has also been described previously (Sato et al.,
1990, 1991). No patient received preoperative hormone
therapy. A list of patient details is available upon request
from the authors.
Tumours and their corresponding non-cancerous tissues
were obtained at surgery from 616 patients with primary
breast cancer. All tissues were dissected in the operating
room, frozen immediately and stored at -80'C until isola-
tion of DNA. Tumours were diagnosed by the pathologists
according to the histological TNM clssification and the
histological typing scheme of the Japanese Breast Cancer
Society, (1989); the tumours included 14 non-invasive ductal
carcinomas, 125 papillotubular carcinomas, 166 solid tubular
carcinomas, 256 scirrhous carcinomas, 21 lobular carcinomas,
six mucinous carcinomas and 28 special-type cancers.
DNA extraction and Southern blotting
Frozen tissue samples were ground to a very fine powder in
liquid nitrogen, suspended in lysis buffer, treated with pro-
teinase K and extracted by phenol-chloroform-isoamyl
alcohol as described elsewhere (Sato et al., 1990). Five micro-
grams of DNA was digested overnight with a 10-fold excess
of restriction enzymes (Boehringer Mannheim) and fraction-
ated by electrophoresis in a 0.8% agarose gel. The DNAs
were then transferred to nylon membranes (Pall; Biodyne) in
0.1 N sodium hydroxide-0.1 M sodium chloride and fixed by
UV cross-linking.
Probes and hybridisation
The DNA markers used in this study, D16S7 (Bufton et al.,
1986), 144D6 (D17S34) (Kondoleon et al., 1987), YNZ22
(D17S5) (Nakamura et al., 1987), C117-701 (D17S870)
(Inazawa et al., 1993), C117-730 (Inazawa et al., 1993) and
C18-134 (D8S177) (Emi et al., 1992), as well as ERBB2
(Yamamoto et al., 1986) have been described previously.
TBAB5.7 (D2S47) on chromosome 2p and EFD64.2 (D3S46)
on chromosome 3q were selected as control probes from the
chromosomal regions where no genetic change is observed in
breast cancer (Bragg et al., 1987; Nakamura et al., 1988).
Probes were labelled with 3P-dCTP by random primer exten-GeIec chnges and hoem recep6ri hbas cancer
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sion (Feinberg and Vogelstein, 1984). Prehybridisation,
hybridisation and autoradiography were carried out as des-
cribed elsewhere (Sato et al., 1990). The membranes were
stripped in 0.4 N sodium hydroxide and repeatedly hybnr-
dised.
Definition ofLOH and amplification
LOH and amplification were assessed by quantification of the
signal intensities or allelic dosage of the polymorphic alleles
be means of a Hoefer GS-300 scanning densitometer as
previously descnibed (Fujiwara et al., 1993). As the difference
in the amount of DNA between paired normal and tumour
DNA may result in an increase or decrease in signal inten-
sities of both alleles in tumour DNA, we measured the
amount of DNA on each lane by ethidium bromide staining
of the gel and compared that amount with the signals
observed by control probes on other chromosomes. Inform-
ation regarding the amount of DNA was taken into con-
sideration when signal intensities for normal and tumour
DNAs were compared. After correction for differences in
DNA loading, the signal intensity of each allele of tumour
DNA was compared with that of DNA from corresponding
normal tissue. Reductions in signal intensity > 50% were
judged as loss of heterozygosity and increases >200% were
judged as amplification.
Oestrogen (ER) andprogesterone receptor (PgR)
determination
ER and PgR were measured by radioreceptor assay in a
standard dextran-coated charcoal (DCC) method, using ['1I1-
oestradiol as labelled ligand on homogenates of fresh-frozen
tissue (Otsuka Pharmaceutical). All samples containing
>5 fmol of ER or PgR per mg protein were considered
receptor positive.
Tabae I Relationship between oestrogen and progesterone receptor
status in 616 breast cancers
PgR(-) PgR(+) Total
ER(-) 147 126 273
ER(+) 46 297 343
Total 193 423 616
ER(-) orPgR(-), oestrogen receptor orprogesterone receptor level
below 5 fmol mg- ' protein. ER( +) or PgR(+), oestrogen receptor or
progesterone receptor level above 5 fmol mg-' protein.
N T N T
Statistical analvses
All statistical analyses were performed using the >-test. One-
tailed P-values <0.05 were considered statistically
significant.
Results
Among the 616 breast tumours examined, 343 (56%) were
positive for ER and 423 (69%) were positive for PgR; 297
were positive for both ER and PgR and 147 were negative
for both ER and PgR (Table I). DNAs from all 616 primary
breast cancers and their corresponding normal tissues were
analysed for the presence or absence of each of five genetic
alterations; LOH at chromosomal regions 16q24, 17pl3.3 and
17q21, and amplification of the c-MYC locus at 8q24 and of
the ERBB2 locus at 17ql1.2. Representative autoradiograms
demonstrating LOH or amplification in breast tumours at the
marker loci are shown in Figure 1. Table II summarises the
frequencies of genetic alterations observed at each of the five
genetic regions studied in this series of tumours; 46% for
LOH at 16q24, 48% for LOH at 17pl133, 39% for LOH at
17q21, 30% for amplification of c-MYC and 20% for
amplification of ERBB2.
We looked for correlations between each of these genetic
alterations and oestrogen/progesterone receptor status.
Results are shown in Tables III and IV. ER-negative status
was more frequent in tumours that had lost one allele at
17q21 (96/173, 56%) than in tumours that retained both
alleles (102/268, 38%) (P<0.0003). Similarly, PgR-negative
status was more frequent in tumours that had lost one allele
at 17q21 (84/173, 49%) than in tumours that retained both
alleles (58/268, 22%) (P<0.0001). Negative status for both
ER and PgR was more frequent in tumours with LOH at
17q21 (67/127, 53%) than in tumours that retained both
alleles (42/192, 22%) (P<0.0001). ER-negative status was
more frequent in tumours with amplification of ERBB2 (67/
103, 65%) than in those without amplification (156/391,
40%) (P<0.0001). PgR-negative status was more frequent in
tumours with amplification of ERBB2 (49!103, 48%) than in
those without amplification at this locus (107/391, 27%)
(P<0.0001). Negative status for both ER and PgR was more
frequent in tumours in which ERBB2 was amplified (29/58,
50%) than in amplification-negative tumours (78/284, 27%)
(P<0.0001).
In addition, PgR-negative status was more frequent in
tumours that had lost alleles at 17pl3.3 (84/224, 38%) than
in tumours that retained both alleles at this locus (65/241,
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Fugwe 1 Representative autoradiograms of Southern blot analysis of DNAs from tumour (T) and normal (N) tissues of primary
breast cancers. DNA were digested with TaqI or MspI and hybridised with each of the probes D16S7, 144D6, YNZ22, C117-701,
C117-730, C18-134 and ERBB2. The autoradiograms demonstrating LOH in tumours are shown for markers D16S7, 144D6,
YNZ22, C117-701 and C117-730; those demonstrating amplification in tumours are shown for markers C18-134 and ERBB2.
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Table H Genetic changes in primary breast cancers
Chromosomal No. ofinformative No. ofcases with
region .Markers Genetic change cases' abnormality
16q24 D16S7 LOH 354 164 (46%)
17pl3.3 D17S34/S5 LOH 465 224 (48%)
17q21 D17S870 LOH 441 173 (39%)
8q24b D8S177 (C-MYC) Amplification 195 59 (30%)
17ql1.2 ERBB2 Amplification 494 103 (20%)
aOf616casesstudied, onlycasesinformative forpolymorphicmarkerwerediagnosed. bExaminedonlyin the
most recent cases.
Tabl m Correlation between genetic alterations and oestrogen
progesterone receptor status
ER PgR
Genetic alteration (-) (+) !-) (+)
16q24
LOH 68 96 51 113
Retain 93 97 NS 67 123 NS
17p13.3
LOH 106 118 84 140
Retain 101 140 NS 65 176 P<0.01
17q21
LOH 96 77 84 89
Retain 102 166 P<0.0003 58 210 P<0.0001
c-MYC
Amp(+) 23 36 20 39
Amp(-) 58 78 NS 39 97 NS
ERBB2
Amp (+) 67 36 49 54
Amp (-) 156 235 P<0.0001 107 284 P<0.0001
NS, not significant; Amp, amplification. ER(-) or PgR(-), oest-
rogen receptor or progesterone receptor level below 5 fmol mg-'
protein. ER(+) or PgR(+), oestrogen receptor or progesterone recep-
tor level above 5 fmol mg-' protein.
27%) (P<0.001). No other genetic alteration was correlated
with oestrogen/progesterone receptor status.
Dcsson
The high frequencies of LOH (39-48%) in three
chromosomal regions, and amplifications (30% and 20%) of
two oncogenes, that we detected in a large series of breast
cancers imply that these genetic changes are not random
events but are associated with development/progression of
breast cancer.
We found that LOH at 17q21 and ERBB2 amplification
were significantly associated with ER- and PgR-negative
state. While we did not detect an association between LOH
at l7pl3.3 and ER-negative status, Thompson et al. (1990)
detected a significant association between them. This dis-
crepancy could be due to differences in sample size, patient
population or other unknown factors between the two
studies. Slamon et al. (1987) and Yamashita et al. (1993)
found no association between ERBB2 amplification and ER-
and PgR-negative state, whereas Borg et al. (1991) and Berns
et al. (1992) have observed a significant association between
them. Our results support the findings of the last studies. It is
worth noting that the number of patients analysed in the last
two studies and in our present study were relatively larger
than those in the other studies. Other genetic alterations, i.e.
LOH at 16q24 and amplification of c-MYC, showed no
association with ER or PgR status. Of tumours having no
Table IV Correlation between genetic alterations and corcordant
oestrogen/progesterone receptor status
Statistical
Genetic alteration Both (- Both (+, significance
16q24 LOH(+) 39 84
LOH(-) 51 81 NS
17pl3.3 LOH(+) 64 98
LOH(-) 50 125 P<0.034
17q21 LOH(+) 67 60
LOH(-) 42 150 P<0.0001
c-MYC Amp(+) 15 31
Amp(-) 31 61 NS
ERBB2 Amp(+) 29 29
Amp(-) 78 206 P<0.00001
NS, not significant. Amp, amplification. ER(-) or PgR(-), oest-
rogen receptor or progesterone receptor level below 5 fmol mg-'
protein. ER(+) or PgR(+), oestrogen receptor or progesterone recep-
tor level above 5 fmnol mg-' protein.
alterations of 17pl3.3, 17q21 or ERBB2, only a small fraction
(18%) were both ER and PgR negative, whereas the majority
(73%) of tumours having all three of the genetic alterations
involving chromosome 17 were ER and PgR negative.
Normal breast epithelial cells and early-stage breast cancer
cells are under the control of oestrogen and other steroid
hormones, but only a third of advanced breast cancers show
oestrogen dependency. Mechanism of this loss of hormone
dependency in breast carcinogenesis is largely unknown.
Strong association of loss of hormone receptors with specific
genetic alterations on chromosome 17, but not with LOH at
16q24 and c-MYC amplification, imply that alteration of
some gene(s) on chromosome 17 might have some relation-
ship to events that render cancer cells independent of hor-
monal control. However, further functional experiments are
necessary to substantiate this notion.
The presence of oestrogen and progesterone receptors in
tumour tissue is a known indicator for good prognosis as
well as for responsiveness to hormonal therapy in breast
cancer; absence of these receptors usually predicts a poor
prognosis and non-responsiveness (Horwitz, 1993). Since
LOH at 17q21, LOH at 17pl3.3 and amplification of ERBB2
was strongly associated with the loss of hormone receptors
and possibly in subsequent hormonal deregulation, these
three genetic alterations might be reflecting a specific aspect
of the molecular biology of malignancy in breast cancer. As
such, they may prove useful in predicting prognosis and
responsiveness to hormonal therapy when used in conjunc-
tion with tests for hormone receptor status.
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